Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
eBay names Cornelius Boone as SVP, Chief People Officer » 16:06
01/20/21
01/20
16:06
01/20/21
16:06
EBAY

eBay

$56.24 /

-0.68 (-1.19%)

, AAL

American Airlines

$16.15 /

+0.17 (+1.06%)

eBay (EBAY) announced the…

eBay (EBAY) announced the appointment of Cornelius Boone as SVP, Chief People Officer. In this role, Cornelius will be responsible for all aspects of human resources across eBay. He will drive business performance, talent development and acquisition, learning and development, compensation, benefits, HR shared services, and people tools and technologies. He will also provide oversight of eBay's Diversity, Equity, and Inclusion team and initiatives. Cornelius will report directly to Jamie Iannone, eBay's CEO and will join the company in early February. Cornelius brings exceptional experience across all facets of human resource strategy and development on a global scale, most recently overseeing the People functions for American Airlines Group (AAL).

ShowHide Related Items >><<
EBAY eBay
$56.24 /

-0.68 (-1.19%)

AAL American Airlines
$16.15 /

+0.17 (+1.06%)

EBAY eBay
$56.24 /

-0.68 (-1.19%)

12/08/20 Baird
eBay trends improving following post-election lull, says Baird
11/27/20 Truist
Amazon to claim 42c of every e-commerce dollar spent, says Truist
11/04/20 BMO Capital
PayPal price target lowered to $193 from $200 at BMO Capital
11/03/20 KeyBanc
PayPal price target lowered to $215 from $230 at KeyBanc
AAL American Airlines
$16.15 /

+0.17 (+1.06%)

01/14/21 Susquehanna
American Airlines price target raised to $10 from $8 at Susquehanna
01/11/21 Cowen
American Airlines downgraded to Market Perform from Outperform at Cowen
12/23/20 Citi
Airline demand in early 2021 'looks soft,' says Citi
12/11/20 Deutsche Bank
American Airlines downgraded to Hold from Buy at Deutsche Bank
EBAY eBay
$56.24 /

-0.68 (-1.19%)

AAL American Airlines
$16.15 /

+0.17 (+1.06%)

  • 10
    Nov
  • 23
    Jun
EBAY eBay
$56.24 /

-0.68 (-1.19%)

AAL American Airlines
$16.15 /

+0.17 (+1.06%)

EBAY eBay
$56.24 /

-0.68 (-1.19%)

AAL American Airlines
$16.15 /

+0.17 (+1.06%)

EBAY eBay
$56.24 /

-0.68 (-1.19%)

AAL American Airlines
$16.15 /

+0.17 (+1.06%)

Yesterday
Hot Stocks
eBay initiates strategic alternatives process for Korea business » 16:46
01/19/21
01/19
16:46
01/19/21
16:46
EBAY

eBay

$56.92 /

+1.5 (+2.71%)

eBay has initiated a…

eBay has initiated a process to explore, review, and evaluate a range of strategic alternatives for its Korea business. The company is "considering options that would maximize value for its shareholders and create future growth opportunities for the business."

ShowHide Related Items >><<
EBAY eBay
$56.92 /

+1.5 (+2.71%)

EBAY eBay
$56.92 /

+1.5 (+2.71%)

12/08/20 Baird
eBay trends improving following post-election lull, says Baird
11/27/20 Truist
Amazon to claim 42c of every e-commerce dollar spent, says Truist
11/04/20 BMO Capital
PayPal price target lowered to $193 from $200 at BMO Capital
11/03/20 KeyBanc
PayPal price target lowered to $215 from $230 at KeyBanc
EBAY eBay
$56.92 /

+1.5 (+2.71%)

EBAY eBay
$56.92 /

+1.5 (+2.71%)

EBAY eBay
$56.92 /

+1.5 (+2.71%)

EBAY eBay
$56.92 /

+1.5 (+2.71%)

Hot Stocks
eBay initiates strategic alternatives process for Korea business » 16:46
01/19/21
01/19
16:46
01/19/21
16:46
EBAY

eBay

$56.92 /

+1.5 (+2.71%)

eBay has initiated a…

eBay has initiated a process to explore, review, and evaluate a range of strategic alternatives for its Korea business. The company is "considering options that would maximize value for its shareholders and create future growth opportunities for the business."

ShowHide Related Items >><<
EBAY eBay
$56.92 /

+1.5 (+2.71%)

EBAY eBay
$56.92 /

+1.5 (+2.71%)

12/08/20 Baird
eBay trends improving following post-election lull, says Baird
11/27/20 Truist
Amazon to claim 42c of every e-commerce dollar spent, says Truist
11/04/20 BMO Capital
PayPal price target lowered to $193 from $200 at BMO Capital
11/03/20 KeyBanc
PayPal price target lowered to $215 from $230 at KeyBanc
EBAY eBay
$56.92 /

+1.5 (+2.71%)

EBAY eBay
$56.92 /

+1.5 (+2.71%)

EBAY eBay
$56.92 /

+1.5 (+2.71%)

EBAY eBay
$56.92 /

+1.5 (+2.71%)

Friday
Recommendations
Mimecast price target lowered to $70 from $77 at Northland » 09:12
01/15/21
01/15
09:12
01/15/21
09:12
MIME

Mimecast

$45.22 /

-0.37 (-0.81%)

, PFPT

Proofpoint

$134.26 /

-1.1 (-0.81%)

Northland analyst Nehal…

Northland analyst Nehal Chokshi lowered the firm's price target on Mimecast (MIME) to $70 from $77 after the company announced that a low single digit number of customers had been targeted by a compromised Mimecast-issued certificate for authentication with Microsoft (MSFT) O365 services. Chokshi, who believes it is likely that Proofpoint's (PFPT) unique Emerging Threats Intelligence unit would more likely have detected and stopped the sophisticated threat actor Mimecast cited, is reducing his long-term growth view for Mimecast to be in line with Proofpoint's, leading to the lowered price target. Chokshi keeps an Outperform rating on Mimecast shares.

ShowHide Related Items >><<
PFPT Proofpoint
$134.26 /

-1.1 (-0.81%)

MIME Mimecast
$45.22 /

-0.37 (-0.81%)

MIME Mimecast
$45.22 /

-0.37 (-0.81%)

01/11/21 Jefferies
Jefferies downgrades 'show me story' Mimecast to Hold from Buy
01/11/21 Jefferies
Mimecast downgraded to Hold from Buy at Jefferies
01/06/21 Barclays
Mimecast price target raised to $62 from $49 at Barclays
01/03/21 BMO Capital
Mimecast downgraded to Market Perform from Outperform at BMO Capital
PFPT Proofpoint
$134.26 /

-1.1 (-0.81%)

01/12/21 Mizuho
Proofpoint price target raised to $130 from $115 at Mizuho
12/31/20 BTIG
Proofpoint price target raised to $157 from $151 at BTIG
11/30/20
Fly Intel: Top five analyst upgrades
11/30/20 Truist
Proofpoint upgraded to Buy from Hold at Truist
PFPT Proofpoint
$134.26 /

-1.1 (-0.81%)

MIME Mimecast
$45.22 /

-0.37 (-0.81%)

PFPT Proofpoint
$134.26 /

-1.1 (-0.81%)

PFPT Proofpoint
$134.26 /

-1.1 (-0.81%)

MIME Mimecast
$45.22 /

-0.37 (-0.81%)

MIME Mimecast
$45.22 /

-0.37 (-0.81%)

Over a week ago
Recommendations
Alnylam price target raised to $197 from $154 at Cowen » 08:47
01/13/21
01/13
08:47
01/13/21
08:47
ALNY

Alnylam

$165.65 /

+9.1 (+5.81%)

Cowen analyst Ritu Baral…

Cowen analyst Ritu Baral raised the firm's price target on Alnylam to $197 from $154 and keeps an Outperform rating on the shares. The analyst noted preliminary revenues were inline with estimates and showed continued geographically even growth. The company also has healthy reserves which should fuel progress across the expanded preclinical and clinical pipeline.

ShowHide Related Items >><<
ALNY Alnylam
$165.65 /

+9.1 (+5.81%)

ALNY Alnylam
$165.65 /

+9.1 (+5.81%)

01/11/21 B. Riley Securities
Dicerna price target raised to $37 from $30 at B. Riley Securities
12/21/20 RBC Capital
Alnylam price target lowered to $144 from $150 at RBC Capital
12/20/20 Piper Sandler
Inclisiran CRL 'a surprise,' not big negative for Alnylam, says Piper Sandler
12/17/20 Piper Sandler
Alnylam price target raised to $181 from $169 at Piper Sandler
ALNY Alnylam
$165.65 /

+9.1 (+5.81%)

ALNY Alnylam
$165.65 /

+9.1 (+5.81%)

ALNY Alnylam
$165.65 /

+9.1 (+5.81%)

Recommendations
Proofpoint price target raised to $130 from $115 at Mizuho » 06:48
01/12/21
01/12
06:48
01/12/21
06:48
PFPT

Proofpoint

$137.41 /

+0.66 (+0.48%)

Mizuho analyst Gregg…

Mizuho analyst Gregg Moskowitz raised the firm's price target on Proofpoint to $130 from $115 and keeps a Neutral rating on the shares. While economic challenges associated with COVID-19 remain, software channel checks continue to show improvement with respect to spend, Moskowitz tells investors in a research note. Companies that enable digitization are still leading the way, although many legacy and/or on-premises technologies are normalizing, says the analyst.

ShowHide Related Items >><<
PFPT Proofpoint
$137.41 /

+0.66 (+0.48%)

PFPT Proofpoint
$137.41 /

+0.66 (+0.48%)

12/31/20 BTIG
Proofpoint price target raised to $157 from $151 at BTIG
11/30/20
Fly Intel: Top five analyst upgrades
11/30/20 Truist
Proofpoint upgraded to Buy from Hold at Truist
11/16/20 SMBC Nikko
Proofpoint initiated with an Outperform at SMBC Nikko
PFPT Proofpoint
$137.41 /

+0.66 (+0.48%)

PFPT Proofpoint
$137.41 /

+0.66 (+0.48%)

PFPT Proofpoint
$137.41 /

+0.66 (+0.48%)

Recommendations
Dicerna price target raised to $37 from $30 at B. Riley Securities » 08:44
01/11/21
01/11
08:44
01/11/21
08:44
DRNA

Dicerna

$23.28 /

+0.39 (+1.70%)

, ALNY

Alnylam

$146.98 /

+7.39 (+5.29%)

B. Riley Securities…

B. Riley Securities analyst Mayank Mamtani raised the firm's price target on Dicerna Pharmaceuticals (DRNA) to $37 from $30 and reiterates a Buy rating on the shares. The analyst believes nedosiran will be a "fast follower" to Alnylam's marketed RNAi drug, Oxlumo. Dicerna is one of his top picks for 2021.

ShowHide Related Items >><<
DRNA Dicerna
$23.28 /

+0.39 (+1.70%)

ALNY Alnylam
$146.98 /

+7.39 (+5.29%)

DRNA Dicerna
$23.28 /

+0.39 (+1.70%)

08/07/20 H.C. Wainwright
Dicerna price target raised to $35 from $32 at H.C. Wainwright
07/01/20 Baird
Dicerna elevated to Fresh Pick at Baird
05/12/20 RBC Capital
Dicerna initiated with an Outperform at RBC Capital
05/11/20 Truist
Dicerna price target raised to $33 from $28 at SunTrust
ALNY Alnylam
$146.98 /

+7.39 (+5.29%)

12/21/20 RBC Capital
Alnylam price target lowered to $144 from $150 at RBC Capital
12/20/20 Piper Sandler
Inclisiran CRL 'a surprise,' not big negative for Alnylam, says Piper Sandler
12/17/20 Piper Sandler
Alnylam price target raised to $181 from $169 at Piper Sandler
11/24/20 BMO Capital
Alnylam price target raised to $183 at BMO Capital on early Oxlumo approval
DRNA Dicerna
$23.28 /

+0.39 (+1.70%)

ALNY Alnylam
$146.98 /

+7.39 (+5.29%)

ALNY Alnylam
$146.98 /

+7.39 (+5.29%)

ALNY Alnylam
$146.98 /

+7.39 (+5.29%)

Hot Stocks
Alnylam trading resumes  07:30
01/07/21
01/07
07:30
01/07/21
07:30
ALNY

Alnylam

$126.99 /

-0.42 (-0.33%)

 
ShowHide Related Items >><<
ALNY Alnylam
$126.99 /

-0.42 (-0.33%)

ALNY Alnylam
$126.99 /

-0.42 (-0.33%)

12/21/20 RBC Capital
Alnylam price target lowered to $144 from $150 at RBC Capital
12/20/20 Piper Sandler
Inclisiran CRL 'a surprise,' not big negative for Alnylam, says Piper Sandler
12/17/20 Piper Sandler
Alnylam price target raised to $181 from $169 at Piper Sandler
11/24/20 BMO Capital
Alnylam price target raised to $183 at BMO Capital on early Oxlumo approval
ALNY Alnylam
$126.99 /

-0.42 (-0.33%)

ALNY Alnylam
$126.99 /

-0.42 (-0.33%)

ALNY Alnylam
$126.99 /

-0.42 (-0.33%)

Hot Stocks
Alnylam announces HELIOS-A study met primary, both secondary endpoints » 07:27
01/07/21
01/07
07:27
01/07/21
07:27
ALNY

Alnylam

$126.99 /

-0.42 (-0.33%)

Alnylam announced that…

Alnylam announced that the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated, or ATTR, amyloidosis, met its primary and both secondary endpoints at nine months in patients with hATTR amyloidosis with polyneuropathy. The primary endpoint was the change from baseline in the modified Neuropathy Impairment Score, or mNIS+7, at nine months as compared to historical placebo data from the APOLLO Phase 3 study of patisiran. The two secondary endpoints were changes in quality of life assessed by the Norfolk Quality of Life Questionnaire-Diabetic Neuropathy, or Norfolk QoL-DN, and gait speed assessed by the timed 10-meter walk test, or 10-MWT, compared to historical placebo. Vutrisiran met the primary endpoint and achieved statistically significant results for each of the Norfolk QoL-DN and 10-MWT secondary endpoints. In addition, vutrisiran treatment showed improvement compared to placebo on the exploratory cardiac biomarker endpoint, NT-proBNP. Vutrisiran also demonstrated an encouraging safety and tolerability profile. Based on these positive results, the company plans to submit a new drug application, or NDA, for vutrisiran with the FDA in early 2021, and to follow with regulatory filings in additional countries, such as Brazil and Japan. The company plans to submit a marketing authorization application, or MAA, in the EU upon obtaining the results of the 18-month analysis - expected in late 2021 - as previously aligned with the European Medicines Agency, or EMA. HELIOS-A is a Phase 3 global, randomized, open-label study to evaluate the efficacy and safety of vutrisiran. The study enrolled 164 patients with hATTR amyloidosis with polyneuropathy at 57 sites in 22 countries. Patients were randomized 3:1 to receive either 25mg of vutrisiran via subcutaneous injection once every three months or 0.3 mg/kg of patisiran via intravenous infusion once every three weeks for 18 months. The primary endpoint is the change from baseline in mNIS+7 score at nine months, relative to historical placebo. Secondary endpoints at nine months are the change from baseline in the Norfolk QoL-DN score and the timed 10-MWT, relative to historical placebo. Changes from baseline in NT-proBNP were evaluated as an exploratory endpoint at nine months. The efficacy results of vutrisiran in HELIOS-A are compared to historical placebo control data from the landmark APOLLO Phase 3 study, which evaluated the efficacy and safety of patisiran in a patient population similar to that studied in HELIOS-A. Additional secondary endpoints at 18 months will be evaluated in the HELIOS-A study, including change from baseline in mNIS+7, Norfolk QoL-DN, 10-MWT, modified body mass index, Rasch-built Overall Disability Scale, and serum transthyretin levels. Additional exploratory cardiac endpoint data at the 18-month time point will be evaluated, including NT-proBNP, echocardiographic measures and cardiac amyloid assessments with technetium scintigraphy imaging. Following the 18-month study period, all patients are eligible to receive vutrisiran for an additional 18 months as part of an open-label extension study. Full 9-month results will be presented at a medical conference in early 2021 and topline 18-month results, including further exploratory cardiac endpoint data, are expected to be announced in late 2021. Vutrisiran demonstrated an encouraging safety profile. There were two study discontinuations due to adverse events in the vutrisiran arm by Month 9, both due to deaths, neither of which was considered related to study drug. There were two serious adverse events deemed related to vutrisiran by the study investigator, consisting of dyslipidemia and urinary tract infection. Treatment emergent adverse events occurring in 10% or more patients included diarrhea, pain in extremity, fall and urinary tract infections, with each of these events occurring at a similar or lower rate as compared with historical placebo. Injection site reactions were reported in five patients and were all mild and transient. There were no clinically significant changes in liver function tests.

ShowHide Related Items >><<
ALNY Alnylam
$126.99 /

-0.42 (-0.33%)

ALNY Alnylam
$126.99 /

-0.42 (-0.33%)

12/21/20 RBC Capital
Alnylam price target lowered to $144 from $150 at RBC Capital
12/20/20 Piper Sandler
Inclisiran CRL 'a surprise,' not big negative for Alnylam, says Piper Sandler
12/17/20 Piper Sandler
Alnylam price target raised to $181 from $169 at Piper Sandler
11/24/20 BMO Capital
Alnylam price target raised to $183 at BMO Capital on early Oxlumo approval
ALNY Alnylam
$126.99 /

-0.42 (-0.33%)

ALNY Alnylam
$126.99 /

-0.42 (-0.33%)

ALNY Alnylam
$126.99 /

-0.42 (-0.33%)

Hot Stocks
Alnylam trading halted, news pending  06:55
01/07/21
01/07
06:55
01/07/21
06:55
ALNY

Alnylam

$126.99 /

-0.42 (-0.33%)

 
ShowHide Related Items >><<
ALNY Alnylam
$126.99 /

-0.42 (-0.33%)

ALNY Alnylam
$126.99 /

-0.42 (-0.33%)

12/21/20 RBC Capital
Alnylam price target lowered to $144 from $150 at RBC Capital
12/20/20 Piper Sandler
Inclisiran CRL 'a surprise,' not big negative for Alnylam, says Piper Sandler
12/17/20 Piper Sandler
Alnylam price target raised to $181 from $169 at Piper Sandler
11/24/20 BMO Capital
Alnylam price target raised to $183 at BMO Capital on early Oxlumo approval
ALNY Alnylam
$126.99 /

-0.42 (-0.33%)

ALNY Alnylam
$126.99 /

-0.42 (-0.33%)

ALNY Alnylam
$126.99 /

-0.42 (-0.33%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.